HHS plan makes progress in ensuring availability of safe vaccines.

CPhI report shows R&D market diversifying with increased partnerships, mergers, and revenue sharing models.

Impact Analytical's facility in Michigan adds staff and instrumentation.

Beckman Coulter partners with Wyatt Technology to develop and market products for nanoparticle characterization.

Pfizer initiates nationwide voluntary recall of two lots Effexor XR and one lot Greenstone's Venlafaxine HCI.

Johnson Controls launches Integrated Laboratory Services for R&D facility operations and scientific productivity.

Agencies extend successful pilot program to further harmonization of QbD topics.

FDA approves the extended-release Bydureon Pen for the treatment of type 2 diabetes.

Novartis calls for more research to understand and find treatments for rare disease.

New guidance from FDA asks for documentation of CMC postapproval manufacturing changes.

China's regulatory and compliance environment is set to change as the government declares a crackdown on bribery scandals.

Conference sessions from PDA and PharmTech expand educational opportunities at INTERPHEX 2014.

The root cause of drug shortages is mismanagement of variation.

USP evaluates quality attributes for synthetic peptides.

Lilly Diabetes supports the American Diabetes Association for the seventh year in a row.

MedImmune and AstraZeneca enter a three-year collaboration with the Clinical and Translational Science Institute at the UC San Francisco.

Discovery of split and broken tablets led to drug recalls.

Experts note hepatitis C screening is important for getting care early.

AbbVie launches art initiative designed to explore impact of chronic inflammatory diseases.

The cyclotron is key component of MPI Research's Translational Imaging Center in Mattawan, Michigan.

Moody's Investor Service reports AbbVie, Amgen, and Roche are the most exposed to biosimilar competition.

FDA approves the orphan drug Myalept for the treatment of leptin deficiency.

Almac has added new blistering technology at their US packaging facility in Audubon, PA, as a solution to ease the transition between clinical and commercial launch of blister products.

Fluid Imaging Technologies calls for submissions for its Life Sciences & Materials Research Grant.

FDA revises interpretation of the five-year NCE exclusivity provisions for certain fixed-combination drug products.

Nuevolution enters a license agreement with a subsidiary of Merck for small molecule compounds.

Daiichi Sankyo announced suspension of API shipments from Ranbaxy's Toansa and Dewas plants; issues apology to stakeholders.

FDA and EMA set up regular meetings to harmonize drug safety actions.